ASXL1基因突变在急性髓系白血病中的研究进展
收稿日期: 2021-03-08
网络出版日期: 2022-08-08
基金资助
甘肃省科技计划项目(20JR5RA595)
徐娜娜, 吴涛, 寇明坤, 白海 . ASXL1基因突变在急性髓系白血病中的研究进展[J]. 内科理论与实践, 2022 , 17(04) : 353 -355 . DOI: 10.16138/j.1673-6087.2022.04.017
| [1] | Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447. |
| [2] | Schuettengruber B, Bourbon HM, Di Croce L, et al. Genome regulation by polycomb and trithorax: 70 years and counting[J]. Cell, 2017, 171(1): 34-57. |
| [3] | Fujino T, Kitamura T. ASXL1 mutation in clonal hematopoiesis[J]. Exp Hematol, 2020, 83: 74-84. |
| [4] | Inoue D, Fujino T, Sheridan P, et al. A novel ASXL1-OGT axis plays roles in H3K4 methylation and tumor suppression in myeloid malignancies[J]. Leukemia, 2018, 32(6): 1327-1337. |
| [5] | Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the polycomb repressive complex PR-DUB[J]. Nature, 2010, 465(7295): 243-247. |
| [6] | Hsu YC, Chiu YC, Lin CC, et al. The distinct biological implications of ASXL1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model[J]. J Hematol Oncol, 2017, 10(1): 1-15. |
| [7] | Zhang P, Chen Z, Li R, et al. Loss of ASXL1 in the bone marrow niche dysregulates hematopoietic stem and progenitor cell fates[J]. Cell Discov, 2018, 4: 4. |
| [8] | 周柰岑, 李国辉, 秦炜炜, 等. 伴ASXL1基因突变的急性髓系白血病患者的临床特征及预后分析[J]. 中国实验血液学杂志, 2021, 29(6):1741-1745. |
| [9] | Kakosaiou K, Panitsas F, Daraki A, et al. ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics[J]. Leuk Lymphoma, 2018, 59(10): 2439-2446. |
| [10] | Kitamura T. ASXL1 mutations gain a function[J]. Blood, 2018, 131(3): 274-275. |
| [11] | Prats-Martín C, Burillo-Sanz S, Morales-Camacho RM, et al. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype[J]. Cancer Med, 2020, 9(11): 3637-3646. |
| [12] | 林云. 伴ASXL1基因突变成人初诊急性髓系白血病的临床特征及预后研究[D]. 福建医科大学, 2016. |
| [13] | Alvarez Argote J, Dasanu CA. ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival[J]. Curr Med Res Opin, 2018, 34(5): 757-763. |
| [14] | Liu F, Gong M, Gao L, et al. RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia[J]. Onco Targets Ther, 2017, 10: 4143-4151. |
| [15] | Devillier R, Mansat-De Mas V, Gelsi-Boyer V, et al. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes[J]. Oncotarget, 2015, 6(10): 8388-8396. |
| [16] | 滕广帅, 王颖韶, 徐晶, 等. ASXL1突变的髓系肿瘤患者共突变基因谱及其临床意义[J]. 天津医药, 2018, 46(12): 1295-1299. |
| [17] | Makishima H. Somatic SETBP1 mutations in myeloid neoplasms[J]. Int J Hematol, 2017, 105(6): 732-742. |
| [18] | 王双玲, 林建雄, 刘峰, 等. TET2在急性髓系白血病中的突变情况及其临床特征[J]. 中国实用医药, 2019, 14(31): 1-3. |
| [19] | Bera R, Chiu MC, Huang YJ, et al. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia[J]. J Hematol Oncol, 2019, 12(1): 104-122. |
| [20] | Nagase R, Inoue D, Pastore A, et al. Expression of mutant ASXL1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation[J]. J Exp Med, 2018, 215(6): 1729-1747. |
| [21] | Carbuccia N, Trouplin V, Gelsi-Boyer V, et al. Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias[J]. Leukemia, 2010, 24(2): 469-473. |
| [22] | 胡晋君.TET2(rs2454206、rs12498609)及ASXL1(rs3746609) 单核苷酸多态性与MDS及其向AML转化的相关性研究[D]. 山西医科大学,2019. |
/
| 〈 |
|
〉 |
